$BVAXF $BIOV.CSE 100% survival on burkholderia challenge.
UK government and DTRA team picking DPX.
Platform earning validation from credible sources.
https://x.com/biovaxys/status/2087603946890399953
$BVAXF $BIOV.CSE CSE simplifying Form 7 requirements helps issuers, but BIOV's real blocker is filing completion lifting the halt.
Aug 19 DoD notification could shift momentum while compliance catches up.
Platform keeps earning credibility.
$BVAXF This is exactly the kind of independent signal that matters. BioVaxys’ PI on the PESCO ovarian study just took home the 2026 IGCS Lifetime Achievement Award.
$BVAXF $BIOV.CSE Dr. Oza receiving IGCS Lifetime Achievement Award validates the clinical leadership running DPX trials.
PESCO study with MVP-S advancing. Platform earning credibility from the people who matter.
Aug 19 validation checkpoint coming.
https://x.com/biovaxys/status/2087312269768073376
$BVAXF CSE simplifying rules by ditching monthly Form 7s is a small positive for the exchange.
Now if BioVaxys can just clear the overdue filings and lift the halt, the underlying DPX tech and earlier positive readouts in ovarian/bladder get a chance to drive the conversation again.
$BVAXF $BIOV.CSE Aug 19 matters because it's a DoD panel evaluating BIOV/Sona acral melanoma work, separate from BIOV's own narrative.
External validation happening while the halt sits.
Platform gets credibility from people with zero financial exposure to the stock.
